AE Management for CAR-T Therapy: Expert Insights and Perspectives
Samer Al'Hadidi, MD, provides a comprehensive overview of adverse event management practices for patients with multiple myeloma who receive CAR T-cell therapy.
Video content above is prompted by the following questions:
- Please discuss AE management practices for CAR T-cell therapy.
- What are some adverse events seen with ide-cel and cilta-cel?
- Review some strategies to help manage AEs.
- How do they compare with bispecifics?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
